In focus · trending topic

HER2CLIMB

8 stories · following the connections

Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress

By Nasdaq OMXSep 11, 2017, 10:00 AM UTC

Cascadian Therapeutics Announces Poster Presentations on Tucatinib in Multiple Tumor Types at the European Society for Medical Oncology (ESMO) 2017 Congress

By Nasdaq OMXAug 28, 2017, 12:30 PM UTC

Cascadian Therapeutics Reports Second Quarter 2017 Financial Results

By Nasdaq OMXAug 8, 2017, 8:01 PM UTC

Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in Europe

By Nasdaq OMXJul 11, 2017, 12:01 PM UTC

Cascadian Therapeutics’ Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases

By Nasdaq OMXJun 8, 2017, 12:01 PM UTC

Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress

By Nasdaq OMXJan 5, 2017, 1:02 PM UTC

Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress

By Nasdaq OMXJan 5, 2017, 1:02 PM UTC

Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress

By Nasdaq OMXJan 5, 2017, 1:02 PM UTC